{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T02:21:29Z","timestamp":1790043689553,"version":"4.0.1"},"reference-count":122,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000},"content-version":"vor","delay-in-days":593,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1016\/j.ymgme.2011.08.004","type":"journal-article","created":{"date-parts":[[2011,8,15]],"date-time":"2011-08-15T00:43:37Z","timestamp":1313369017000},"page":"438-447","source":"Crossref","is-referenced-by-count":60,"title":["Therapeutic approaches to bone pathology in Gaucher disease: Past, present and future"],"prefix":"10.1016","volume":"104","author":[{"given":"Ozlem","family":"Goker-Alpan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2011.08.004_bb0005","series-title":"The Online Metabolic and Molecular Bases of Inherited Disease","first-page":"3635","article-title":"Gaucher disease","author":"Beutler","year":"2006"},{"key":"10.1016\/j.ymgme.2011.08.004_bb0010","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1067\/S0022-3476(03)00302-0","article-title":"Phenotypic continuum in neuronopathic Gaucher disease: an intermediate phenotype between type 2 and type 3","volume":"143","author":"Goker-Alpan","year":"2003","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0015","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/qjmed\/hch036","article-title":"Twin pairs showing discordance of phenotype in adult Gaucher's disease","volume":"97","author":"Lachmann","year":"2004","journal-title":"QJM"},{"key":"10.1016\/j.ymgme.2011.08.004_bb0020","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1023\/B:BOLI.0000042983.60840.f3","article-title":"Gaucher disease: variability in phenotype among siblings","volume":"27","author":"Amato","year":"2004","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0025","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1136\/jmg.2004.028019","article-title":"Divergent phenotypes in Gaucher disease implicate the role of modifiers","volume":"42","author":"Goker-Alpan","year":"2005","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0030","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/BF00687792","article-title":"Reactions of vessel walls and brain parenchyma to the accumulation of Gaucher cells in the Norrbottnian type (type III) of Gaucher disease","volume":"75","author":"Conradi","year":"1988","journal-title":"Acta Neuropathol."},{"issue":"Suppl 1","key":"10.1016\/j.ymgme.2011.08.004_bb0035","doi-asserted-by":"crossref","first-page":"A2","DOI":"10.1259\/bjr.75.suppl_1.750002","article-title":"Skeletal aspects of Gaucher disease: a review","volume":"75","author":"Wenstrup","year":"2002","journal-title":"Br. J. Radiol."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0040","series-title":"Gaucher Disease: A Century of Delineation","first-page":"107","article-title":"Bone involvement in Gaucher disease","author":"Beighton","year":"1982"},{"key":"10.1016\/j.ymgme.2011.08.004_bb0045","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/j.1399-0004.2007.00811.x","article-title":"Imiglucerase (Cerezyme) improves quality of life in patients with skeletal manifestations of Gaucher disease","volume":"71","author":"Weinreb","year":"2007","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0050","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/00005792-198509000-00003","article-title":"Skeletal complications of Gaucher disease","volume":"64","author":"Stowens","year":"1985","journal-title":"Medicine"},{"key":"10.1016\/j.ymgme.2011.08.004_bb0055","doi-asserted-by":"crossref","first-page":"33","DOI":"10.7326\/0003-4819-122-1-199501010-00005","article-title":"Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources","volume":"122","author":"Grabowski","year":"1995","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0060","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.bcmd.2010.07.008","article-title":"Early achievement and maintenance of the therapeutic goals using velaglucerase alfa in type 1 Gaucher disease","volume":"46","author":"Elstein","year":"2011","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0065","doi-asserted-by":"crossref","first-page":"e4792","DOI":"10.1371\/journal.pone.0004792","article-title":"A plant-derived recombinant human glucocerebrosidase enzyme\u2014a preclinical and phase I investigation","volume":"4","author":"Aviezer","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ymgme.2011.08.004_bb0070","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/MD.0b013e3182057be4","article-title":"Osseous manifestations of adult Gaucher disease in the era of enzyme replacement therapy","volume":"90","author":"Deegan","year":"2011","journal-title":"Medicine"},{"key":"10.1016\/j.ymgme.2011.08.004_bb0075","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0002-9343(02)01150-6","article-title":"Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5years of treatment: a report from the Gaucher Registry","volume":"113","author":"Weinreb","year":"2002","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0080","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.seminhematol.2004.07.009","article-title":"Therapeutic goals in the treatment of Gaucher disease","volume":"41","author":"Pastores","year":"2004","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0085","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1001\/archinternmed.2010.302","article-title":"Type 1 Gaucher disease: significant disease manifestations in \"asymptomatic\" homozygotes","volume":"170","author":"Balwani","year":"2010","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0090","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2141.2009.07872.x","article-title":"Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis","volume":"147","author":"Mistry","year":"2009","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0095","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.bcmd.2010.10.011","article-title":"Osteopenia in Gaucher disease develops early in life: response to imiglucerase enzyme therapy in children, adolescents and adults","volume":"46","author":"Mistry","year":"2011","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0100","first-page":"S131","article-title":"Normal bone anatomy and physiology","author":"Barthe","year":"2008","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"54","key":"10.1016\/j.ymgme.2011.08.004_bb0105","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1600-0757.2010.00355.x","article-title":"Osteoclastic bone resorption induced by innate immune responses","volume":"2000","author":"Koide","year":"2010","journal-title":"Periodontol."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0110","doi-asserted-by":"crossref","first-page":"7260","DOI":"10.1073\/pnas.87.18.7260","article-title":"Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells","volume":"87","author":"Udagawa","year":"1990","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0115","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1615\/CritRevEukarGeneExpr.v19.i3.10","article-title":"Osteoclasts have multiple roles in bone in addition to bone resorption","volume":"19","author":"Boyce","year":"2009","journal-title":"Crit. Rev. Eukaryot. Gene Expr."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0120","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1001\/archinte.160.18.2835","article-title":"The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease","volume":"160","author":"Charrow","year":"2000","journal-title":"Archives of Internal Medicine"},{"key":"10.1016\/j.ymgme.2011.08.004_bb0125","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bcmd.2010.10.014","article-title":"Impact of imiglucerase on the serum glycosylated-ferritin level in Gaucher disease","volume":"46","author":"Stirnemann","year":"2011","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0130","first-page":"85","article-title":"Gaucher disease: gene frequencies in the Ashkenazi Jewish population","volume":"52","author":"Beutler","year":"1993","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0135","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2214\/AJR.07.3550","article-title":"Correlation of MRI-Based bone marrow burden score with genotype and spleen status in Gaucher's disease","volume":"191","author":"DeMayo","year":"2008","journal-title":"AJR Am. J. Roentgenol."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0140","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/ajh.21362","article-title":"The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients","volume":"84","author":"Taddei","year":"2009","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0145","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1002\/jbmr.5650111125","article-title":"Bone density in Type 1 Gaucher disease","volume":"11","author":"Pastores","year":"1996","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0150","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S0950-3536(97)80041-8","article-title":"Skeletal involvement in Gaucher's disease","volume":"10","author":"Elstein","year":"1997","journal-title":"Bailliere's Clin. Haematol."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0155","first-page":"267","article-title":"Skeletal manifestations in Gaucher disease: presentation and treatment","volume":"1","author":"Lebel","year":"1999","journal-title":"Isr. Med. Assoc. J."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0160","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s11926-000-0059-x","article-title":"Bone and joint complications related to Gaucher disease","volume":"2","author":"Pastores","year":"2000","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0165","first-page":"37","article-title":"Orthopaedic manifestations of Gaucher disease","volume":"65","author":"Lutsky","year":"2007","journal-title":"Bull. NYU Hosp. Joint Dis."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0170","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/ajh.21280","article-title":"A benchmark analysis of the achievement of therapeutic goals for type 1 Gaucher disease patients treated with imiglucerase","volume":"83","author":"Weinreb","year":"2008","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0175","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.bcmd.2009.04.003","article-title":"The female Gaucher patient: the impact of enzyme replacement therapy around key reproductive events (menstruation, pregnancy and menopause)","volume":"43","author":"Zimran","year":"2009","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0180","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ejogrb.2010.12.024","article-title":"The management of pregnancy in Gaucher disease","volume":"156","author":"Granovsky-Grisaru","year":"2011","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0185","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ajog.2003.08.006","article-title":"Pregnancies in Gaucher disease: a 5-year study","volume":"190","author":"Elstein","year":"2004","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0190","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.2106\/00004623-198668090-00011","article-title":"Osteomyelitis in Gaucher disease","volume":"68","author":"Bell","year":"1986","journal-title":"J. Bone Joint Surg. Am."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0195","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1080\/00016470410004003","article-title":"Orthopedic considerations in Gaucher disease since the advent of enzyme replacement therapy","volume":"75","author":"Itzchaki","year":"2004","journal-title":"Acta Orthop. Scand."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0200","first-page":"201","article-title":"Risk factors for osteonecrosis in patients with type 1 Gaucher's disease","author":"Rodrigue","year":"1999","journal-title":"Clin. Orthop. Relat. Res."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0205","doi-asserted-by":"crossref","first-page":"19473","DOI":"10.1073\/pnas.1003308107","article-title":"Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage","volume":"107","author":"Mistry","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ymgme.2011.08.004_bb0210","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s00198-010-1342-y","article-title":"Vertebral fractures in Gaucher disease type I: data from the French \"Observatoire\" on Gaucher disease (FROG)","volume":"22","author":"Javier","year":"2011","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0215","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/archpedi.160.6.603","article-title":"The clinical and demographic characteristics of nonneuronopathic Gaucher disease in 887 children at diagnosis","volume":"160","author":"Kaplan","year":"2006","journal-title":"Arch. Pediatr. Adolesc. Med."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0220","first-page":"158","article-title":"Delayed growth and puberty in patients with Gaucher disease type 1: natural history and effect of splenectomy and\/or enzyme replacement therapy","volume":"2","author":"Kauli","year":"2000","journal-title":"Isr Med Assoc J"},{"key":"10.1016\/j.ymgme.2011.08.004_bb0225","series-title":"Clinical Outcomes of Long-term (8Years) Enzyme Replacement Therapy in 884 Children with Type 1 Gaucher Disease [Abstract] 5th Symposium on Lysosomal Storage Disorders, Paris, France","first-page":"30","author":"Andersson","year":"2008"},{"issue":"Suppl. 1","key":"10.1016\/j.ymgme.2011.08.004_bb0230","doi-asserted-by":"crossref","first-page":"A37","DOI":"10.1259\/bjr.75.suppl_1.750037","article-title":"Bone complications in children with Gaucher disease","volume":"75","author":"Bembi","year":"2002","journal-title":"Br. J. Radiol."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0235","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0002-9343(97)00134-4","article-title":"Differential effects of enzyme supplementation therapy on manifestations of type 1 Gaucher disease","volume":"103","author":"Hollak","year":"1997","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0240","first-page":"2653","article-title":"Increased basal glucose production in type 1 Gaucher's disease","volume":"80","author":"Corssmit","year":"1995","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0245","first-page":"31","article-title":"Body composition and bone metabolism in young Gaucher disease type I patients treated with imiglucerase","volume":"13","author":"Parisi","year":"2008","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0250","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1309\/BG5VA8JRDQH1M7HN","article-title":"Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages","volume":"122","author":"Boven","year":"2004","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0255","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1172\/JCI117084","article-title":"Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease","volume":"93","author":"Hollak","year":"1994","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0260","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1007\/s10545-006-0318-8","article-title":"CCL18: a urinary marker of Gaucher cell burden in Gaucher patients","volume":"29","author":"Boot","year":"2006","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0265","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1651-2227.2007.00641.x","article-title":"Biomarkers for lysosomal storage disorders: identification and application as exemplified by chitotriosidase in Gaucher disease","volume":"97","author":"Aerts","year":"2008","journal-title":"Acta Paediatr. Suppl."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0270","series-title":"Chapter 7: evaluating bone remodeling, osteoporosis: prevention","author":"Notelovitz","year":"1997"},{"key":"10.1016\/j.ymgme.2011.08.004_bb0275","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.bcmd.2005.08.004","article-title":"Increased incidence of cancer in adult Gaucher disease in Western Europe","volume":"36","author":"de Fost","year":"2006","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0280","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1182\/blood-2004-12-4672","article-title":"Gaucher disease and cancer incidence: a study from the Gaucher Registry","volume":"105","author":"Rosenbloom","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ymgme.2011.08.004_bb0285","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/qjmed\/90.1.19","article-title":"Pro-inflammatory cytokines and the pathogenesis of Gaucher's disease: increased release of interleukin-6 and interleukin-10","volume":"90","author":"Allen","year":"1997","journal-title":"QJM"},{"key":"10.1016\/j.ymgme.2011.08.004_bb0290","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1006\/bcmd.1997.0156","article-title":"Cytokine mRNA in Gaucher disease","volume":"23","author":"Lichtenstein","year":"1997","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0295","first-page":"205","article-title":"Cytokines in Gaucher's disease","volume":"10","author":"Barak","year":"1999","journal-title":"Eur. Cytokine Netw."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0300","doi-asserted-by":"crossref","first-page":"11846","DOI":"10.1074\/jbc.M512624200","article-title":"Tumor necrosis factor-alpha increases circulating osteoclast precursor numbers by promoting their proliferation and differentiation in the bone marrow through up-regulation of c-Fms expression","volume":"281","author":"Yao","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0305","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1210\/jc.2011-0162","article-title":"Markers of bone turnover in Gaucher disease: modeling the evolution of bone disease","volume":"96","author":"van Dussen","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0310","doi-asserted-by":"crossref","first-page":"325","DOI":"10.2174\/1568010054022015","article-title":"Osteoblasts and osteoclasts in bone remodeling and inflammation","volume":"4","author":"Tanaka","year":"2005","journal-title":"Curr. Drug Targets Inflamm. Allergy"},{"key":"10.1016\/j.ymgme.2011.08.004_bb0315","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1093\/clinchem\/47.8.1443","article-title":"Interlaboratory variation of biochemical markers of bone turnover","volume":"47","author":"Seibel","year":"2001","journal-title":"Clin. Chem."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0320","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s10545-005-0032-y","article-title":"Gaucher disease and bone: laboratory and skeletal mineral density variations during a long period of enzyme replacement therapy","volume":"28","author":"Ciana","year":"2005","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0325","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1182\/blood-2009-02-205708","article-title":"Characterization of Gaucher disease bone marrow mesenchymal stromal cells reveals an altered inflammatory secretome","volume":"114","author":"Campeau","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ymgme.2011.08.004_bb0330","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/01.GIM.0000153660.88672.3C","article-title":"Individualization of long-term enzyme replacement therapy for Gaucher disease","volume":"7","author":"Andersson","year":"2005","journal-title":"Genet. Med"},{"key":"10.1016\/j.ymgme.2011.08.004_bb0335","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1185\/030079906X104623","article-title":"Evidence-based recommendations for monitoring bone disease and the response to enzyme replacement therapy in Gaucher patients","volume":"22","author":"Vom Dahl","year":"2006","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0340","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s10545-008-0779-z","article-title":"Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring","volume":"31","author":"Cox","year":"2008","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0345","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1148\/radiology.182.2.1732964","article-title":"Quantitative chemical shift imaging of vertebral bone marrow in patients with Gaucher disease","volume":"182","author":"Johnson","year":"1992","journal-title":"Radiology"},{"key":"10.1016\/j.ymgme.2011.08.004_bb0350","doi-asserted-by":"crossref","first-page":"961","DOI":"10.2214\/ajr.179.4.1790961","article-title":"Quantification of skeletal involvement in adults with type I Gaucher's disease: fat fraction measured by Dixon quantitative chemical shift imaging as a valid parameter","volume":"179","author":"Maas","year":"2002","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.ymgme.2011.08.004_bb0355","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1006\/bcmd.2001.0474","article-title":"Dixon quantitative chemical shift imaging is a sensitive tool for the evaluation of bone marrow responses to individualized doses of enzyme supplementation therapy in type 1 Gaucher disease","volume":"27","author":"Hollak","year":"2001","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0360","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1148\/radiol.2292020296","article-title":"Quantification of bone involvement in Gaucher disease: MR imaging bone marrow burden score as an alternative to Dixon quantitative chemical shift MR imaging\u2014initial experience","volume":"229","author":"Maas","year":"2003","journal-title":"Radiology"},{"key":"10.1016\/j.ymgme.2011.08.004_bb0365","doi-asserted-by":"crossref","DOI":"10.1055\/s-0029-1245410","article-title":"MRI Bone Marrow Findings in 63 Patients with Type I Gaucher Disease","author":"Poll","year":"2010","journal-title":"Rofo"},{"key":"10.1016\/j.ymgme.2011.08.004_bb0370","first-page":"1253","article-title":"Severity of bone marrow involvement in patients with Gaucher's disease evaluated by scintigraphy with 99mTc-sestamibi","volume":"44","author":"Mariani","year":"2003","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0375","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/BPO.0b013e3180340d9f","article-title":"Use of plain radiography to optimize skeletal outcomes in children with type 1 Gaucher disease in Brazil","volume":"27","author":"Mota","year":"2007","journal-title":"J. Pediatr. Orthop."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0380","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00256-007-0425-0","article-title":"Recommendations for the assessment and monitoring of skeletal manifestations in children with Gaucher disease","volume":"37","author":"Maas","year":"2008","journal-title":"Skeletal Radiol."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0385","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jpeds.2007.02.057","article-title":"Clinical consequences of interrupting enzyme replacement therapy in children with type 1 Gaucher disease","volume":"151","author":"Drelichman","year":"2007","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0390","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1542\/peds.96.4.629","article-title":"Enzyme replacement therapy for Gaucher disease: skeletal responses to macrophage-targeted glucocerebrosidase","volume":"96","author":"Rosenthal","year":"1995","journal-title":"Pediatrics"},{"issue":"Suppl. 1","key":"10.1016\/j.ymgme.2011.08.004_bb0395","doi-asserted-by":"crossref","first-page":"A25","DOI":"10.1259\/bjr.75.suppl_1.750025","article-title":"Response of Gaucher bone disease to enzyme replacement therapy","volume":"75","author":"Poll","year":"2002","journal-title":"Br. J. Radiol."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0400","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1006\/bcmd.2002.0511","article-title":"Correlation of bone marrow response with hematological, biochemical, and visceral responses to enzyme replacement therapy of nonneuronopathic (type 1) Gaucher disease in 30 adult patients","volume":"28","author":"Poll","year":"2002","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0405","first-page":"2131","article-title":"The application of the vertebra-disc ratio in a population of patients with Gaucher's disease","volume":"8","author":"Vlieger","year":"2000","journal-title":"Proc. Intl. Soc. Magn. Reson. Med."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0410","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.2214\/AJR.06.1410","article-title":"Semiquantitative assessment of skeletal response to enzyme replacement therapy for Gaucher's disease using the bone marrow burden score","volume":"188","author":"Robertson","year":"2007","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.ymgme.2011.08.004_bb0415","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/s002560100375","article-title":"Magnetic resonance imaging of bone marrow changes in Gaucher disease during enzyme replacement therapy: first German long-term results","volume":"30","author":"Poll","year":"2001","journal-title":"Skeletal Radiol."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0420","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1359\/jbmr.061004","article-title":"Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease","volume":"22","author":"Wenstrup","year":"2007","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0425","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/j.1399-0004.2008.00978.x","article-title":"Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study","volume":"75","author":"Sims","year":"2008","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0430","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1542\/peds.2007-2144","article-title":"Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1","volume":"122","author":"Andersson","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2011.08.004_bb0435","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1006\/bcmd.2002.0517","article-title":"Decreased bone density in splenectomized Gaucher patients receiving enzyme replacement therapy","volume":"28","author":"Schiffmann","year":"2002","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0440","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s00774-004-0529-8","article-title":"Bone density changes with enzyme therapy for Gaucher disease","volume":"22","author":"Lebel","year":"2004","journal-title":"J. Bone Miner. Metab."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0445","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1006\/bcmd.1998.0195","article-title":"Low-dose high-frequency enzyme replacement therapy prevents fractures without complete suppression of painful bone crises in patients with severe juvenile onset type I Gaucher disease","volume":"24","author":"Cohen","year":"1998","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0450","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1126\/science.1589760","article-title":"Gaucher disease: new molecular approaches to diagnosis and treatment","volume":"256","author":"Beutler","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.ymgme.2011.08.004_bb0455","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1006\/bcmd.1995.0012","article-title":"The clinical course of treated and untreated Gaucher disease. A study of 45 patients","volume":"21","author":"Beutler","year":"1995","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0460","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1023\/A:1005451300167","article-title":"Severe skeletal complications in Japanese patients with type 1 Gaucher disease","volume":"22","author":"Ida","year":"1999","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0465","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s002560000276","article-title":"Bone marrow response in treated patients with Gaucher disease: evaluation by T1-weighted magnetic resonance images and correlation with reduction in liver and spleen volume","volume":"29","author":"Terk","year":"2000","journal-title":"Skeletal Radiol."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0470","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1182\/blood.V82.2.408.408","article-title":"Enzyme therapy in Gaucher disease type 1: dosage efficacy and adverse effects in 33 patients treated for 6 to 24months","volume":"82","author":"Pastores","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.ymgme.2011.08.004_bb0475","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1006\/bcmd.1996.0016","article-title":"Effect of low-dose enzyme replacement therapy on bones in Gaucher disease patients with severe skeletal involvement","volume":"22","author":"Elstein","year":"1996","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0480","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1399-0004.2007.00769.x","article-title":"The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease","volume":"71","author":"Charrow","year":"2007","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0485","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3324\/haematol.10635","article-title":"Low frequency maintenance therapy with imiglucerase in adult type I Gaucher disease: a prospective randomized controlled trial","volume":"92","author":"de Fost","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.ymgme.2011.08.004_bb0490","first-page":"647","article-title":"Imiglucerase low-dose therapy for paediatric Gaucher disease\u2014a long-term cohort study","volume":"94","author":"Heitner","year":"2004","journal-title":"S. Afr. Med. J. = Suid-Afrikaanse Tydskrif vir Geneeskunde"},{"key":"10.1016\/j.ymgme.2011.08.004_bb0495","doi-asserted-by":"crossref","DOI":"10.1517\/14656560903270520","article-title":"Enzyme therapy for the treatment of type 1 Gaucher disease: clinical outcomes and dose - response relationships","author":"Hollak","year":"2009","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0500","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ymgme.2008.12.015","article-title":"A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4weeks versus every 2weeks in the maintenance therapy of adult patients with Gaucher disease type 1","volume":"96","author":"Kishnani","year":"2009","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0505","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.1365-2141.1993.tb03224.x","article-title":"Low-dose high-frequency enzyme replacement therapy for very young children with severe Gaucher disease","volume":"85","author":"Zimran","year":"1993","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0510","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1056\/NEJM199212033272304","article-title":"A less costly regimen of alglucerase to treat Gaucher's disease","volume":"327","author":"Figueroa","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0515","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ymgme.2007.05.013","article-title":"The outcome of clinical parameters in adults with severe Type I Gaucher disease using very low dose enzyme replacement therapy","volume":"92","author":"Wilson","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0520","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1080\/08880010290097143","article-title":"Type I Gaucher disease in children with and without enzyme therapy","volume":"19","author":"Dweck","year":"2002","journal-title":"Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0525","first-page":"80","article-title":"Children with type I Gaucher disease: growing into adulthood with and without enzyme therapy","volume":"2","author":"Zimran","year":"2000","journal-title":"Isr Med Assoc J"},{"key":"10.1016\/j.ymgme.2011.08.004_bb0530","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.bcmd.2009.08.002","article-title":"The clinical course of untreated Gaucher disease in 22 patients over 10years: hematological and skeletal manifestations","volume":"43","author":"Piran","year":"2009","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0535","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/00005792-199211000-00002","article-title":"Gaucher disease. Clinical, laboratory, radiologic, and genetic features of 53 patients","volume":"71","author":"Zimran","year":"1992","journal-title":"Medicine"},{"key":"10.1016\/j.ymgme.2011.08.004_bb0540","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1182\/blood-2005-12-5072","article-title":"Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2-center retrospective analysis","volume":"108","author":"de Fost","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ymgme.2011.08.004_bb0545","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.3324\/haematol.12651","article-title":"Persistent bone disease in adult type 1 Gaucher disease despite increasing doses of enzyme replacement therapy","volume":"93","author":"de Fost","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.ymgme.2011.08.004_bb0550","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/ajh.2830470325","article-title":"Pathologic fractures may develop in Gaucher patients receiving enzyme replacement therapy","volume":"47","author":"Sidransky","year":"1994","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0555","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/glycob\/cwp138","article-title":"Characterization of gene-activated human acid-{beta}-glucosidase: crystal structure, glycan composition and internalization into macrophages","volume":"20","author":"Brumshtein","year":"2010","journal-title":"Glycobiology"},{"key":"10.1016\/j.ymgme.2011.08.004_bb0560","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1467-7652.2007.00263.x","article-title":"Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system","volume":"5","author":"Shaaltiel","year":"2007","journal-title":"Plant Biotechnol. J."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0565","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1093\/glycob\/cwm008","article-title":"Effect of mannose chain length on targeting of glucocerebrosidase for enzyme replacement therapy of Gaucher disease","volume":"17","author":"Van Patten","year":"2007","journal-title":"Glycobiology"},{"key":"10.1016\/j.ymgme.2011.08.004_bb0570","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.bcmd.2011.04.005","article-title":"Significant and continuous improvement in bone mineral density among type 1 Gaucher disease patients treated with velaglucerase alfa: 69-month experience, including dose reduction","volume":"47","author":"Elstein","year":"2011","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0575","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/S0140-6736(00)02161-9","article-title":"Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis","volume":"355","author":"Cox","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ymgme.2011.08.004_bb0580","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/j.clinthera.2007.08.006","article-title":"Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies","volume":"29","author":"Pastores","year":"2007","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0585","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1182\/blood-2007-02-075960","article-title":"Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement","volume":"110","author":"Elstein","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ymgme.2011.08.004_bb0590","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/pds.1779","article-title":"Miglustat (Zavesca(R)) in type 1 Gaucher disease: 5-year results of a post-authorisation safety surveillance programme","volume":"18","author":"Hollak","year":"2009","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0595","doi-asserted-by":"crossref","DOI":"10.1007\/s10545-010-9193-4","article-title":"Dietary modifications in patients receiving miglustat","author":"Champion","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2011.08.004_bb0600","first-page":"1169","article-title":"Eliglustat tartrate, an orally active glucocerebroside synthase inhibitor for the potential treatment of Gaucher disease and other lysosomal storage diseases","volume":"11","author":"Cox","year":"2010","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.ymgme.2011.08.004_bb0605","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2010-03-273151","article-title":"A Phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1","volume":"116","author":"Lukina","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ymgme.2011.08.004_bb0610","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1182\/blood-2010-06-293902","article-title":"Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study","volume":"116","author":"Lukina","year":"2010","journal-title":"Blood"}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719211002575?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719211002575?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T18:32:19Z","timestamp":1686249139000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719211002575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":122,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S1096719211002575"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2011.08.004","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}